First Time Loading...

Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
XBRU:HYL
Watchlist
Price: 11.7 EUR Market Closed
Updated: May 29, 2024

Profitability Summary

29/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Hyloris Pharmaceuticals SA

Revenue
2.8m EUR
Cost of Revenue
-93k EUR
Gross Profit
2.7m EUR
Operating Expenses
-18.8m EUR
Operating Income
-16.1m EUR
Other Expenses
327k EUR
Net Income
-15.8m EUR

Margins Comparison
Hyloris Pharmaceuticals SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
BE
Hyloris Pharmaceuticals SA
XBRU:HYL
327.6m EUR
97%
-572%
-560%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
767.8B USD
80%
32%
17%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
85%
45%
37%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
347.5B USD
70%
28%
45%
US
Merck & Co Inc
NYSE:MRK
319.3B USD
75%
10%
4%
UK
AstraZeneca PLC
LSE:AZN
186.5B GBP
82%
18%
13%
CH
Roche Holding AG
SIX:ROG
182.4B CHF
73%
32%
20%
CH
Novartis AG
SIX:NOVN
178.3B CHF
74%
28%
30%
US
Pfizer Inc
NYSE:PFE
160.4B USD
70%
19%
-1%
Country BE
Market Cap 327.6m EUR
Gross Margin
97%
Operating Margin
-572%
Net Margin
-560%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 767.8B USD
Gross Margin
80%
Operating Margin
32%
Net Margin
17%
Country DK
Market Cap 4.1T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
37%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country US
Market Cap 347.5B USD
Gross Margin
70%
Operating Margin
28%
Net Margin
45%
Country US
Market Cap 319.3B USD
Gross Margin
75%
Operating Margin
10%
Net Margin
4%
Country UK
Market Cap 186.5B GBP
Gross Margin
82%
Operating Margin
18%
Net Margin
13%
Country CH
Market Cap 182.4B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 178.3B CHF
Gross Margin
74%
Operating Margin
28%
Net Margin
30%
Country US
Market Cap 160.4B USD
Gross Margin
70%
Operating Margin
19%
Net Margin
-1%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Hyloris Pharmaceuticals SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
BE
Hyloris Pharmaceuticals SA
XBRU:HYL
327.6m EUR
-34%
-29%
-33%
-111%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
767.8B USD
51%
10%
28%
17%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
100%
33%
87%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
347.5B USD
52%
21%
19%
14%
US
Merck & Co Inc
NYSE:MRK
319.3B USD
5%
2%
7%
4%
UK
AstraZeneca PLC
LSE:AZN
186.5B GBP
17%
6%
12%
10%
CH
Roche Holding AG
SIX:ROG
182.4B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
178.3B CHF
38%
17%
22%
17%
US
Pfizer Inc
NYSE:PFE
160.4B USD
0%
0%
6%
1%
Country BE
Market Cap 327.6m EUR
ROE
-34%
ROA
-29%
ROCE
-33%
ROIC
-111%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 767.8B USD
ROE
51%
ROA
10%
ROCE
28%
ROIC
17%
Country DK
Market Cap 4.1T DKK
ROE
100%
ROA
33%
ROCE
87%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country US
Market Cap 347.5B USD
ROE
52%
ROA
21%
ROCE
19%
ROIC
14%
Country US
Market Cap 319.3B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
4%
Country UK
Market Cap 186.5B GBP
ROE
17%
ROA
6%
ROCE
12%
ROIC
10%
Country CH
Market Cap 182.4B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 178.3B CHF
ROE
38%
ROA
17%
ROCE
22%
ROIC
17%
Country US
Market Cap 160.4B USD
ROE
0%
ROA
0%
ROCE
6%
ROIC
1%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More